Pascal Girard
Merck KGaA, Darmstadt (Germany) · 138 works · 3,127 citations · h-index 30
Top works
- An Effect Model for the Assessment of Drug Benefit
- A Markov mixed effect regression model for drug compliance
- Population pharmacokinetics of midazolam in neonates
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
- Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?
- Do we need full compliance data for population pharmacokinetic analysis?
- A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
- Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model
- Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey
- A pharmacokinetic simulation model for ivabradine in healthy volunteers
- New methods of quantitative assessment of the extent and significance of serial ECG changes of the repolarization phase
- First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
- Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris
- Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent
- Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
- Predictors of prescription errors involving anticancer chemotherapy agents
- Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods
- Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
- Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
- A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers